valiantsin suprunovich/iStock via Getty Images A majority of an expert panel convened by the U.S. FDA found that there is "reasonable assurance" that Guardant Health's ( NASDAQ: GH ) Shield blood test for colorectal cancer screening is effective for patients.
The vote was 6-3. Members of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee also voted 7-2 that the benefits of the test outweigh the risks. Trading in Guardant Health ( GH ) was halted Thursda y in advance of the meeting.
As of 5p ET, the halt had yet to be lifted. Exact Sciences ( EXAS ), which markets its own colorectal cancer screening test, Cologuard, is down ~7.5% in after-hours trading Thursday.
More on Guardant Health Guardant Health slips as FDA comments on cancer screening test Guardant Health: Shield Launch Could Drive Multiple Expansion Guardant Health, Inc. (GH) Q1 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Guardant Health.
